|
|
Neurology February 2009
Volume 72
Issue 7
| This Week in Neurology(R) |
this week in neurology(r): highlights of the february 17 issue.
Pages: 583
|
| Editorials |
picturing injury and recovery with diffusion tensor imaging: the eyes have it.
- Bermel, Robert, Fox, Robert. Pages: 584-585
|
brain atrophy as an outcome measure for multiple sclerosis clinical trials: a "no-brainer"?
- Rudick, Richard, Fisher, Elizabeth. Pages: 586-587
|
| In Memoriam |
wayne alfred hening, md, phd (1945-2008).
- Allen, Richard, Walters, Arthur, Chokroverty, Sudhansu, MD, FRCP. Pages: 588
|
| Articles |
disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities.
- Naismith, R, Xu, J, Tutlam, N, Snyder, A, MD, PhD, Benzinger, T, MD, PhD, Shimony, J, MD, PhD, Shepherd, J, Trinkaus, K, Cross, A, Song, S-K. Pages: 589-594
>
Show/Hide Abstract
Objective: To determine the potential of directional diffusivities from diffusion tensor imaging (DTI) to predict clinical outcome of optic neuritis (ON), and correlate with vision, optical coherence tomography (OCT), and visual evoked potentials (VEP).Methods: Twelve cases of acute and isolated ON were imaged within 30 days of onset and followed prospectively. Twenty-eight subjects with a remote clinical history of ON were studied cross-sectionally. Twelve healthy controls were imaged for comparison. DTI data were acquired at 3T with a surface coil and 1.3 x 1.3 x 1.3 mm3 isotropic voxels.Results: Normal DTI parameters (mean +/- SD, [mu]m2/ms) were axial diffusivity = 1.66 +/- 0.18, radial diffusivity = 0.81 +/- 0.26, apparent diffusion coefficient (ADC) = 1.09 +/- 0.21, and fractional anisotropy (FA) = 0.43 +/- 0.15. Axial diffusivity decreased up to 2.5 SD in acute ON. The decrease in axial diffusivity at onset correlated with visual contrast sensitivity 1 month (r = 0.59) and 3 months later (r = 0.65). In three subjects followed from the acute through the remote stage, radial diffusivity subsequently increased to >2.5 SD above normal, as did axial diffusivity and ADC. In remote ON, radial diffusivity correlated with OCT (r = 0.81), contrast sensitivity (r = 0.68), visual acuity (r = 0.56), and VEP (r = 0.54).Conclusion: In acute and isolated demyelination, axial diffusivity merits further investigation as a predictor of future clinical outcome. Diffusion parameters are dynamic in acute and isolated optic neuritis, with an initial acute decrease in axial diffusivity. In remote disease, radial diffusivity correlates with functional, structural, and physiologic tests of vision.(C)2009AAN Enterprises, Inc.
|
sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.
- Altmann, D, Jasperse, B, Barkhof, F, Beckmann, K, Filippi, M, Kappos, L, Molyneux, P, Polman, C, Pozzilli, C, Thompson, A, Wagner, K, Yousry, T, Miller, D. Pages: 595-601
>
Show/Hide Abstract
Background: Progressive brain atrophy in multiple sclerosis (MS) may reflect neuroaxonal and myelin loss and MRI measures of brain tissue loss are used as outcome measures in MS treatment trials. This study investigated sample sizes required to demonstrate reduction of brain atrophy using three outcome measures in a parallel group, placebo-controlled trial for secondary progressive MS (SPMS).Methods: Data were taken from a cohort of 43 patients with SPMS who had been followed up with 6-monthly T1-weighted MRI for up to 3 years within the placebo arm of a therapeutic trial. Central cerebral volumes (CCVs) were measured using a semiautomated segmentation approach, and brain volume normalized for skull size (NBV) was measured using automated segmentation (SIENAX). Change in CCV and NBV was measured by subtraction of baseline from serial CCV and SIENAX images; in addition, percentage brain volume change relative to baseline was measured directly using a registration-based method (SIENA). Sample sizes for given treatment effects and power were calculated for standard analyses using parameters estimated from the sample.Results: For a 2-year trial duration, minimum sample sizes per arm required to detect a 50% treatment effect at 80% power were 32 for SIENA, 69 for CCV, and 273 for SIENAX. Two-year minimum sample sizes were smaller than 1-year by 71% for SIENAX, 55% for CCV, and 44% for SIENA.Conclusion: SIENA and central cerebral volume are feasible outcome measures for inclusion in placebo-controlled trials in secondary progressive multiple sclerosis.(C)2009AAN Enterprises, Inc.
|
demyelinating events in early multiple sclerosis have inherent severity and recovery.
- Mowry, E, Pesic, M, Grimes, B, Deen, S, Bacchetti, P, Waubant, E, MD, PhD. Pages: 602-608
>
Show/Hide Abstract
Background: It is unclear whether the severity of and recovery from the initial demyelinating event (IDE) are recapitulated in subsequent multiple sclerosis (MS) relapses. We sought to identify the factors associated with relapse severity and recovery and to evaluate whether events have inherent severity or recovery.Methods: Patients seen at the UCSF MS Clinic within 1 year of disease onset were identified from a prospective database. Ordinal logistic regression was used to analyze predictors of three-level categorizations of event severity and recovery.Results: We identified 330 patients with MS or clinically isolated syndrome; 152 had a second event and 63 had a third event. Nonwhite and younger patients were at an increased risk of more severe demyelinating events. A severe prior event predicted a substantial increase in the odds of being above any given severity cutoff for a severe subsequent event (for second event severity, odds ratio [OR] = 5.62, 95% confidence interval [CI] [2.39, 13.26], p < 0.0001; for third event severity, OR = 6.74, 95% CI [1.67, 27.18], p = 0.007). Similarly, poor recovery of the IDE predicted poor second event recovery (OR = 5.28, 95% CI [1.95, 14.25], p = 0.001), while fair or poor second event recovery predicted about a 5- or 13-fold increase in the odds of poor third event recovery. A more severe event also predicted a substantial increase in the odds of poor recovery.Conclusions: Patients with severe presentation and poor recovery at disease onset continue on a similar trajectory with subsequent demyelinating events. Whether genetic or other biologic factors are responsible for this pattern remains to be determined.(C)2009AAN Enterprises, Inc.
|
ngf, dcx, and nse upregulation correlates with severity and outcome of head trauma in children.
- Chiaretti, A, Barone, G, Riccardi, R, Antonelli, A, Pezzotti, P, Genovese, O, Tortorolo, L, Conti, G. Pages: 609-616
>
Show/Hide Abstract
Background: Secondary brain damage after traumatic brain injury (TBI) involves neuroinflammatory mechanisms, mainly dependent on the intracerebral production of specific biomarkers, such as cytokines, neurotrophic factors, and neuron-specific enolase (NSE). NSE is associated with neuronal damage, while neurotrophic factors play a neuroprotective role due to their ability to modulate neuronal precursor biosynthesis, such as doublecortin (DCX). However, the relationships between the expression of these factors and the severity and outcome of TBI are not understood.Methods: To determine whether the concentrations of neurotrophic factors (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF], glial-derived neurotrophic factor [GDNF]), DCX, and NSE in the CSF of children with TBI correlate with the severity of brain damage and neurologic outcome, we prospectively collected CSF samples from 32 children at 2 and 48 hours after admission for severe TBI and from 32 matched controls. Severity of TBI was evaluated by Glasgow Coma Scale and neurologic outcome by Glasgow Outcome Score.Results: Early NGF, DCX, and NSE concentrations correlated significantly with the severity of head injury, whereas no correlation was found for BDNF and GDNF. Furthermore, NGF and DCX upregulation and lower NSE expression were associated with better neurologic outcomes. No significant association was found between BDNF and GDNF expression and outcome.Conclusions: Nerve growth factor (NGF), doublecortin (DCX), and neuron-specific enolase concentrations in the CSF are useful markers of brain damage following severe traumatic brain injury (TBI). NGF and DCX upregulation correlates also with better neurologic outcome and could be useful to obtain clinical and prognostic information in children with severe TBI.(C)2009AAN Enterprises, Inc.
|
a novel frabin (fgd4) nonsense mutation p.r275x associated with phenotypic variability in cmt4h.
- Houlden, Henry, MD, PhD, Hammans, Simon, Katifi, Haider, Reilly, Mary. Pages: 617-620
>
Show/Hide Abstract
Background: Charcot Marie Tooth (CMT) disease is a heterogeneous group of inherited peripheral motor and sensory neuropathies. CMT4H is an early onset autosomal recessive demyelinating neuropathy. The locus responsible for CMT4H was assigned to chromosome 12p11.21-q13.11 by homozygosity mapping and mutations in the Frabin gene (FGD4 Rho GDP/GTP exchange factor) were subsequently identified in six families.Methods: We sequenced the Frabin gene in a cohort of 12 UK CMT families with clinically defined autosomal recessive demyelinating neuropathy.Results: We identified a novel homozygous Frabin p.R275X mutation in a family from Northern Ireland. The two affected cases in this family had a very slowly progressive neuropathy with both cases remaining ambulant into middle age. Examination of mRNA from lymphoblasts showed that this stop mutation caused very little nonsense mediated mRNA decay and the predominant mRNA species was the mutant form that is likely to be translated into a truncated protein.Conclusions: This work extends the understanding of the pathogenesis of Frabin mutation-associated Charcot Marie Tooth (CMT) 4H and suggests that mutations in Frabin should also be considered in ambulant adults with CMT1.(C)2009AAN Enterprises, Inc.
|
b-type natriuretic peptide and cardiovalvulopathy in parkinson disease with dopamine agonist.
- Watanabe, H, Hirayama, M, Noda, A, Ito, M, Atsuta, N, Senda, J, Kaga, T, Yamada, A, Katsuno, M, Niwa, T, Tanaka, F, Sobue, G. Pages: 621-626
>
Show/Hide Abstract
Objective: To elucidate the usefulness of plasma B-type natriuretic peptide (BNP) values for evaluating adverse effects of pergolide or cabergoline on cardiovalvulopathy in patients with Parkinson disease.Methods: Twenty-five patients treated with pergolide or cabergoline (ergot group) and 25 patients never treated with ergot derivatives (non-ergot group) were enrolled. Plasma BNP values and detailed echocardiography were evaluated. Thirty age- and gender-matched controls were similarly evaluated.Results: Patients with regurgitation more than grade 3 were more frequent in the ergot group than in the non-ergot group as well as control groups (24%, 0%, 3%, p = 0.001). Both composite regurgitation scores and plasma BNP values were significantly higher in the ergot group than in controls. In the ergot group, the cumulative dose correlated to both tenting area (r = 0.57, p = 0.004) and tenting distance (r = 0.62, p = 0.001). Furthermore, plasma BNP values were higher in patients with severe or multiple regurgitation groups (p < 0.001), and were correlated with composite regurgitation score (r = 0.70, p < 0.001). Multiple regression analyses revealed that BNP values were independently correlated with both composite regurgitation and left ventricular ejection fraction.Conclusion: The combination of comprehensive echocardiography and plasma B-type natriuretic peptide levels elucidates the presence of cardiac damage in patients with Parkinson disease using ergot derivative dopamine agonists.(C)2009AAN Enterprises, Inc.
|
intracranial arterial wall imaging using high-resolution 3-tesla contrast-enhanced mri.
- Swartz, R, MD, PhD, Bhuta, S, Farb, R, Agid, R, Willinsky, R, terBrugge, K, Butany, J, Wasserman, B, Johnstone, D, RTR, RTMR, Silver, F, Mikulis, D. Pages: 627-634
>
Show/Hide Abstract
Background: Conventional arterial imaging focuses on the vessel lumen but lacks specificity because different pathologies produce similar luminal defects. Wall imaging can characterize extracranial arterial pathology, but imaging intracranial walls has been limited by resolution and signal constraints. Higher-field scanners may improve visualization of these smaller vessels.Methods: Three-tesla contrast-enhanced MRI was used to study the intracranial arteries from a consecutive series of patients at a tertiary stroke center.Results: Multiplanar T2-weighted fast spin echo and multiplanar T1 fluid-attenuated inversion recovery precontrast and postcontrast images were acquired in 37 patients with focal neurologic deficits. Clinical diagnoses included atherosclerotic disease (13), CNS inflammatory disease (3), dissections (3), aneurysms (3), moyamoya syndrome (2), cavernous angioma (1), extracranial source of stroke (5), and no definitive clinical diagnosis (7). Twelve of 13 with atherosclerotic disease had focal, eccentric vessel wall enhancement, 10 of whom had enhancement only in the vessel supplying the area of ischemic injury. Two of 3 with inflammatory diseases had diffuse, concentric vessel wall enhancement. Three of 3 with dissection showed bright signal on T1, and 2 had irregular wall enhancement with a flap and dual lumen.Conclusions: Three-tesla contrast-enhanced MRI can be used to study the wall of intracranial blood vessels. T2 and precontrast and postcontrast T1 fluid-attenuated inversion recovery images at 3 tesla may be able to differentiate enhancement patterns of intracranial atherosclerotic plaques (eccentric), inflammation (concentric), and other wall pathologies. Prospective studies are required to determine the sensitivity and specificity of arterial wall imaging for distinguishing the range of pathologic conditions affecting cerebral vasculature.(C)2009AAN Enterprises, Inc.
|
impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis.
- van der Bilt, I, Hasan, D, MD, PhD, Vandertop, W, MD, PhD, Wilde, A, MD, PhD, Algra, A, MD, PhD, Visser, F, MD, PhD, Rinkel, G, MD, PhD. Pages: 635-642
>
Show/Hide Abstract
Impact of cardiac complications after aneurysmal subarachnoid hemorrhage (SAH) remains controversial. We performed a meta-analysis to assess whether EKG changes, myocardial damage, or echocardiographic wall motion abnormalities (WMAs) are related to death, poor outcome (death or dependency), or delayed cerebral ischemia (DCI) after SAH.Methods: Articles on cardiac abnormalities after aneurysmal SAH that met predefined criteria and were published between 1960 and 2007 were retrieved. We assessed the quality of reports and extracted data on patient characteristics, cardiac abnormalities, and outcome measurements. Poor outcome was defined as death or dependence by the Glasgow Outcome Scale (dichotomized at <=3) or the modified Rankin scale (dichotomized at >3). If studies used another dichotomy or another outcome scale, we used the numbers of patients with poor outcome provided by the authors. We calculated pooled relative risks (RRs) with corresponding 95% confidence intervals for the relation between cardiac abnormalities and outcome measurements.Results: We included 25 studies (16 prospective) with a total of 2,690 patients (mean age 53 years; 35% men). Mortality was associated with WMAs (RR 1.9), elevated troponin (RR 2.0) and brain natriuretic peptide (BNP) levels (RR 11.1), tachycardia (RR 3.9), Q waves (RR 2.9), ST-segment depression (RR 2.1), T-wave abnormalities (RR 1.8), and bradycardia (RR 0.6). Poor outcome was associated with elevated troponin (RR 2.3) and creatine kinase MB (CK-MB) levels (RR 2.3) and ST-segment depression (RR 2.4). Occurrence of DCI was associated with WMAs (RR 2.1), elevated troponin (RR 3.2), CK-MB (RR 2.9), and BNP levels (RR 4.5), and ST-segment depression (RR 2.4). All RRs were significant.Conclusion: Markers for cardiac damage and dysfunction are associated with an increased risk of death, poor outcome, and delayed cerebral ischemia after subarachnoid hemorrhage. Future research should establish whether these cardiac abnormalities are independent prognosticators and should be directed toward pathophysiologic mechanisms and potential treatment options.(C)2009AAN Enterprises, Inc.
|
vasoreactivity and peri-infarct hyperintensities in stroke.
- Zhao, P, Alsop, D, AbdulJalil, A, Selim, M, Lipsitz, L, Novak, P, MD, PhD, Caplan, L, Hu, K, Novak, V, MD, PhD. Pages: 643-649
>
Show/Hide Abstract
Objective: It is unknown if impaired cerebral vasoreactivity recovers after ischemic stroke, and whether it compromises perfusion in regions surrounding infarct and other vascular territories. We investigated the regional differences in CO2 vasoreactivity (CO2VR) and their relationships to peri-infarct T2 hyperintensities (PIHs), chronic infarct volumes, and clinical outcomes.Methods: We studied 39 subjects with chronic large middle cerebral artery territory infarcts and 48 matched controls. Anatomic and three-dimensional continuous arterial spin labeling imaging at 3-Tesla MRI were used to measure regional cerebral blood flow (CBF) and CO2VR during normocapnia, hypercapnia, and hypocapnia in main arteries distributions.Results: Stroke patients showed a significantly lower augmentation of blood flow at increased CO2 but greater reduction of blood flow with decreased CO2 than the control group. This altered vasoregulatory response was observed both ipsilateral and contralateral to the stroke. Lower CO2VR on the stroke side was associated with PIHs, greater infarct volume, and worse outcomes. The cases with PIHs (n = 27) had lower CBF during all conditions bilaterally (p < 0.0001) compared to cases with infarct only.Conclusions: Perfusion augmentation is inadequate in multiple vascular territories in patients with large artery ischemic infarcts, but vasoconstriction is preserved. Peri-infarct T2 hyperintensities are associated with lower blood flow. Strategies aimed to preserve vasoreactivity after an ischemic stroke should be tested for their effect on long-term outcomes.(C)2009AAN Enterprises, Inc.
|
ace d/i polymorphism, migraine, and cardiovascular disease in women.
- Schurks, M, MD, MSc, Zee, R, MD, PhD, Buring, J, Kurth, T, MD, ScD. Pages: 650-656
>
Show/Hide Abstract
Background: Interrelationships among the ACE deletion/insertion (D/I) polymorphism (rs1799752), migraine, and cardiovascular disease (CVD) are biologically plausible but remain controversial.Methods: Association study among 25,000 white US women, participating in the Women's Health Study, with information on the ACE D/I polymorphism. Migraine and migraine aura status were self-reported. Incident CVD events were confirmed after medical record review. We used logistic regression to investigate the genotype-migraine association and proportional hazards models to evaluate the interrelationship among genotype, migraine, and incident CVD.Results: At baseline, 4,577 (18.3%) women reported history of migraine; 39.5% of the 3,226 women with active migraine indicated aura. During 11.9 years of follow-up, 625 CVD events occurred. We did not find an association of the ACE D/I polymorphism with migraine or migraine aura status. There was a lack of association between the ACE D/I polymorphism and incident major CVD, ischemic stroke, and myocardial infarction. Migraine with aura doubled the risk for CVD, but only for carriers of the DD (multivariable-adjusted relative risk [RR] = 2.10; 95% CI = 1.22-3.59; p = 0.007) and DI genotype (multivariable-adjusted RR = 2.31; 95% CI = 1.52-3.51; p < 0.0001). The risk was not significant among carriers of the II genotype, a pattern we observed for myocardial infarction and ischemic stroke.Conclusions: Data from this large cohort of women do not suggest an association of the ACE deletion/insertion (D/I) polymorphism with migraine, migraine aura status, or cardiovascular disease (CVD). The increased risk for CVD among migraineurs with aura was only apparent for carriers of the DD/DI genotype. Due to limited number of outcome events, however, future studies are warranted to further investigate this association.(C)2009AAN Enterprises, Inc.
|
| Views & Reviews |
teaching the next generation of neurologists.
- Elkind, Mitchell, MD, MS. Pages: 657-663
>
Show/Hide Abstract
Educators of the next generation of neurologists will face several challenges, including changes in academic medical centers and hospitals, changes in the scope and practice of neurology itself, and changes in trainees, related to both access to information technology and professional goals. This article, which originated as a lecture given at the A.B. Baker Education Symposium at the 60th annual meeting of the American Academy of Neurology in April 2008, arose out of an attempt to enumerate these challenges and to suggest ways to address them. First, approaches to overcoming challenges will likely require reinvigorating the commitment to teaching in fundamental and concrete ways, including, for example, establishing communities of educators and taking seriously the teaching role provided by clinicians. Second, it is expected that changes in the scope of educational content will be needed. Learning the role of the neurologist in a broader societal context will become an increasingly important part of training. It should be emphasized, as well, that trainees should play an important role in the redesign of neurology training and practice; in fact, their participation in this hidden curriculum constitutes an important part of their education. Third, new information technologies, such as Google, Wikipedias, and podcasting, will likely play an increasingly important role in neurology education. Finally, generational differences in familiarity with these new technologies, and differences in professional and personal goals, may lead to different career opportunities and plans for future neurologists than have been considered the norm in the past.(C)2009AAN Enterprises, Inc.
|
| Clinical Implications of Neuroscience Research |
potassium channels: brief overview and implications in epilepsy.
- Benarroch, Eduardo. Pages: 664-669
>
Show/Hide Abstract
(C)2009AAN Enterprises, Inc.
|
| Clinical/Scientific Notes |
brown-sequard syndrome after herpes zoster.
- Young-Barbee, C, Hall, D, MD, PhD, LoPresti, J, Schmid, D, Gilden, D. Pages: 670-671
|
superficial siderosis: sealing the defect.
- Kumar, Neeraj, Lane, John, Piepgras, David. Pages: 671-673
|
syphilitic myelitis: rare, nonspecific, but treatable.
- Chilver-Stainer, L, Fischer, U, Hauf, M, Fux, C, Sturzenegger, M. Pages: 673-675
|
| NeuroImages |
neuropathic pruritus following wallenberg syndrome.
- Seo, W, Kwon, D, Seo, S, MD, PhD, Park, M, MD, PhD, Park, K, MD, PhD. Pages: 676
|
| Resident & Fellow Section |
international issues: postgraduate neurologic training in japan.
- Nodera, Hiroyuki. Pages: e34-e36
|
video neuroimage: symptomatic sunct syndrome cured after trigeminal neurovascular contact surgical decompression.
- Guerreiro, R, Casimiro, M, Lopes, D, Marques, J, Fontoura, P, MD, PhD. Pages: e37
|
| Correspondence |
neuropathology of brain death in the modern transplant era.
- Evans, David. Pages: 677-678
|
race/ethnic differences in ad survival in us alzheimer's disease centers.
- Lanska, Douglas. Pages: 678
|
| Correction |
improvements in memory function following anterior temporal lobe resection for epilepsy.
Pages: 678
|
| Departments: Book Review |
neurogenetic developmental disorders: variation of manifestation in childhood.
- Patterson, Marc, MD, FRACP. Pages: 679
|
| Departments: Calendar |
calendar.
Pages: 680-681
|
| Future Issues |
in the next issue of neurology(r): volume 72, number 8, february 24, 2009.
Pages: 44A
|
|
|